{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:46:50Z","timestamp":1790221610114,"version":"4.1.0"},"reference-count":138,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Lung cancer, the leading cause of cancer mortality, faces persistent challenges like resistance to targeted therapy and immunotherapy. This review comprehensively outlines the evolving role of bispecific antibodies (bsAbs), summarizing their mechanisms, clinical findings, and future directions. It is timely given emerging data and novel bsAbs that may reshape lung cancer treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>The article covers the development and clinical application of bsAbs in lung cancer, highlighting advancements in production technology and diverse formats. bsAbs are designed to simultaneously bind two different antigens, enabling mechanisms such as immune cell bridging and dual targeting of oncogenic pathways. Key themes include the use of bsAbs as first-line treatments, their role in second-line and later-line settings, and their application in neoadjuvant or adjuvant therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The findings suggest that bsAbs represent a significant advancement in lung cancer treatment, offering new therapeutic strategies to address unmet needs. The development of next-generation bsAbs, including trispecific antibodies and conditional activation platforms, promises enhanced precision and safety. These innovations have the potential to improve outcomes for patients with advanced lung cancer. Future research should focus on optimizing patient selection through biomarker-driven approaches and exploring combination therapies to maximize the benefits of bsAbs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cco.0000000000001206","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T16:00:27Z","timestamp":1762963227000},"page":"54-70","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The evolving landscape of bispecific antibodies in the treatment of lung cancer"],"prefix":"10.1097","volume":"38","author":[{"given":"Xuanhong","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Chang","sequence":"additional","affiliation":[{"name":"Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"R1-20260213","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"R2-20260213","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R3-20260213","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"R4-20260213","doi-asserted-by":"crossref","first-page":"a037895","DOI":"10.1101\/cshperspect.a037895","article-title":"Tumor immunology and immunotherapy of non-small-cell lung cancer","volume":"12","author":"Cascone","year":"2022","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R5-20260213","first-page":"620","article-title":"Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R6-20260213","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"R7-20260213","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"R8-20260213","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40265-021-01561-7","article-title":"Amivantamab: first approval","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"R9-20260213","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-024-02073-w","article-title":"Ivonescimab: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"R10-20260213","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40265-025-02155-3","article-title":"Zenocutuzumab: first approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"key":"R11-20260213","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","article-title":"Tarlatamab: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"R12-20260213","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/305537a0","article-title":"Hybrid hybridomas and their use in immunohistochemistry","volume":"305","author":"Milstein","year":"1983","journal-title":"Nature"},{"key":"R13-20260213","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nbt.2016.12.010","article-title":"Engineering bispecific antibodies with defined chain pairing","volume":"39","author":"Krah","year":"2017","journal-title":"N Biotechnol"},{"key":"R14-20260213","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.3390\/antib7030028","article-title":"Engineering IgG-like bispecific antibodies-an overview","volume":"7","author":"Krah","year":"2018","journal-title":"Antibodies (Basel)"},{"key":"R15-20260213","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"R16-20260213","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges","volume":"201","author":"Suurs","year":"2019","journal-title":"Pharmacol Ther"},{"key":"R17-20260213","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/ijms26125838","article-title":"Bispecific antibodies in solid tumors: advances and challenges","volume":"26","author":"Shan","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R18-20260213","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","article-title":"Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy","volume":"14","author":"Qin","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"R20-20260213","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"R21-20260213","doi-asserted-by":"crossref","first-page":"e14291","DOI":"10.15252\/emmm.202114291","article-title":"The state of the art of bispecific antibodies for treating human malignancies","volume":"13","author":"Wang","year":"2021","journal-title":"EMBO Mol Med"},{"key":"R22-20260213","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.08.005","article-title":"T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics","volume":"182","author":"Wu","year":"2018","journal-title":"Pharmacol Ther"},{"key":"R23-20260213","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s40265-022-01761-9","article-title":"Cadonilimab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"issue":"Suppl 2","key":"R24-20260213","first-page":"A469","article-title":"469 Preclinical studies support clinical development of AZD2936, a monovalent bispecific humanized antibody targeting PD-1 and TIGIT","volume":"10","author":"Karin","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"(Suppl 12)","key":"R25-20260213","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1158\/1538-7445.AM2022-5520","article-title":"Abstract 5520: AK129, an anti-PD1\/LAG-3 bi-specific antibody for cancer therapy","volume":"82","author":"Huang","year":"2022","journal-title":"Cancer Res"},{"key":"R26-20260213","doi-asserted-by":"crossref","first-page":"S755","DOI":"10.1016\/j.annonc.2023.09.2347","article-title":"1313MO Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB\u2013IV nonsmall-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy","volume":"34","author":"Besse","year":"2023","journal-title":"Ann Oncol"},{"key":"R27-20260213","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","article-title":"PD-L1 expression in advanced NSCLC: insights into risk stratification and treatment selection from a systematic literature review","volume":"112","author":"Brody","year":"2017","journal-title":"Lung Cancer"},{"key":"R28-20260213","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cac2.12244","article-title":"Anti-PD-L1\/TGF-(R fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1\/PD-L1 inhibitors in lung cancer","volume":"42","author":"Cheng","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"R29-20260213","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jtho.2023.10.014","article-title":"A Phase 1b study of ivonescimab, a programmed cell death protein-1 and vascular endothelial growth factor bispecific antibody, as first- or second-line therapy for advanced or metastatic immunotherapy-naive NSCLC","volume":"19","author":"Wang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"R30-20260213","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-21-1345","article-title":"Preclinical characterization and Phase I trial results of a bispecific antibody targeting PD-L1 and 4-1BB (GEN1046) in patients with advanced refractory solid tumors","volume":"12","author":"Muik","year":"2022","journal-title":"Cancer Discov"},{"key":"R31-20260213","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1158\/1535-7163.MCT-24-0330","article-title":"A novel designed Anti-PD-L1\/OX40 bispecific antibody augments both peripheral and tumor-associated immune responses for boosting antitumor immunity","volume":"24","author":"Li","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"R32-20260213","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"R33-20260213","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, Phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"issue":"(Suppl 7)","key":"R35-20260213","doi-asserted-by":"crossref","first-page":"LB126","DOI":"10.1158\/1538-7445.AM2024-LB126","article-title":"Abstract LB126: Generation of a novel ROR1 x CD3 bispecific T-cell engager for better tumor killing and minimal cytokine release","volume":"84","author":"Wu","year":"2024","journal-title":"Cancer Res"},{"key":"R37-20260213","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-cancerbio-070620-104325","article-title":"Targeting solid tumors with bispecific T cell engager immune therapy","volume":"6","author":"Arvedson","year":"2022","journal-title":"Annu Rev Cancer Biol"},{"key":"R38-20260213","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-020-02679-5","article-title":"Tumor-selective blockade of CD47 signaling with a CD47\/PD-L1 bispecific antibody for enhanced antitumor activity and limited toxicity","volume":"70","author":"Wang","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"Suppl 2","key":"R39-20260213","first-page":"A514","article-title":"514 AK132, a first-in-class asymmetric Claudin18.2\/CD47 bispecific antibody for cancer immunotherapy","volume":"12","author":"Xinghua","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R40-20260213","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"R41-20260213","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol"},{"key":"R42-20260213","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/1078-0432.CCR-22-2180","article-title":"Preclinical study of a biparatopic METxMET antibody-drug conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC","volume":"29","author":"Oh","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"(Suppl 12)","key":"R43-20260213","doi-asserted-by":"crossref","first-page":"B130","DOI":"10.1158\/1535-7163.TARG-23-B130","article-title":"Abstract B130: Phase 1 study of Zanidatamab Zovodotin (ZW49): safety profile and recommended dose (RD) in patients with human epidermal growth factor 2 (HER2)-positive solid cancers","volume":"22","author":"Oh","year":"2023","journal-title":"Mol Cancer Therap"},{"issue":"Suppl 2","key":"R44-20260213","first-page":"A504","article-title":"504 CS2009, a novel first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFa, demonstrates promising antitumor activity in preclinical evaluation","volume":"12","author":"Chuan","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R46-20260213","doi-asserted-by":"crossref","first-page":"S492","DOI":"10.1016\/j.annonc.2023.09.1897","article-title":"711TiP A phase I\/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR \u00d7 CD3\u03b5 COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors","volume":"34","author":"Weickhardt","year":"2023","journal-title":"Ann Oncol"},{"key":"R47-20260213","first-page":"348","article-title":"Application and future prospects of bispecific antibodies in the treatment of nonsmall cell lung cancer","volume":"22","author":"Wen","year":"2025","journal-title":"Cancer Biol Med"},{"key":"R48-20260213","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive nonsmall cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"issue":"(Suppl 16)","key":"R50-20260213","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1200\/JCO.2025.43.16_suppl.8543","article-title":"A phase II trial to evaluate the safety and efficacy of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, as a monotherapy in patients with advanced NSCLC","volume":"43","author":"Wu","year":"2025","journal-title":"J Clin Oncol"},{"issue":"(Suppl 16)","key":"R51-20260213","doi-asserted-by":"crossref","first-page":"8533","DOI":"10.1200\/JCO.2024.42.16_suppl.8533","article-title":"A phase Ib\/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC","volume":"42","author":"Wu","year":"2024","journal-title":"J Clin Oncol"},{"key":"R52-20260213","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s12916-022-02605-9","article-title":"Bifunctional anti-PD-L1\/TGF-(RII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial","volume":"20","author":"Liu","year":"2022","journal-title":"BMC Med"},{"key":"R53-20260213","doi-asserted-by":"crossref","first-page":"S1667","DOI":"10.1016\/j.annonc.2023.10.590","article-title":"511MO A phase I study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-\u03b2, in patients with advanced nonsmall cell lung cancer (NSCLC)","volume":"34","author":"Feng","year":"2023","journal-title":"Ann Oncol"},{"issue":"(Suppl 15)","key":"R54-20260213","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1200\/JCO.2018.36.15_suppl.9017","article-title":"Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1","volume":"36","author":"Paz-Ares","year":"2018","journal-title":"J Clin Oncol"},{"key":"R55-20260213","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jtho.2023.08.018","article-title":"Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1-high advanced NSCLC: a randomized, open-label, Phase 3 trial","volume":"18","author":"Cho","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R56-20260213","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-024-01644-4","article-title":"The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia\/Ib study","volume":"17","author":"Ruan","year":"2024","journal-title":"J Hematol Oncol"},{"key":"R57-20260213","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"R58-20260213","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR Exon 20 Insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"R61-20260213","doi-asserted-by":"crossref","first-page":"S1671","DOI":"10.1016\/j.annonc.2023.10.595","article-title":"516MO Efficacy and safety of MCLA-129, an anti-EGFR\/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in nonsmall cell lung cancer (NSCLC)","volume":"34","author":"Cappuzzo","year":"2023","journal-title":"Ann Oncol"},{"issue":"(Suppl 16)","key":"R62-20260213","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.1200\/JCO.2025.43.16_suppl.8570","article-title":"SMET12 and toripalimab combined chemotherapy in patients with advanced nonsmall cell lung cancer who are treatment-naive or have developed resistance to standard therapy","volume":"43","author":"Lin","year":"2025","journal-title":"J Clin Oncol"},{"issue":"(8_Suppl_1)","key":"R63-20260213","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1158\/1538-7445.AM2025-3206","article-title":"Abstract 3206: cadonilimabplus chemotherapy as first-line treatment in PD-L1 negative advanced nonsmall cell lung cancer (LungCadX): a phase II study","volume":"85","author":"Wang","year":"2025","journal-title":"Cancer Res"},{"key":"R64-20260213","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41416-023-02519-0","article-title":"A phase Ib\/II study of cadonilimab (PD-1\/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced nonsmall cell lung cancer","volume":"130","author":"Chen","year":"2024","journal-title":"Br J Cancer"},{"key":"R65-20260213","doi-asserted-by":"crossref","first-page":"S1423","DOI":"10.1016\/j.annonc.2022.08.058","article-title":"LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin\/pemetrexed (CP) in treatment-na\u00efve (1L) nonsmall cell lung cancer (NSCLC): a phase Ib\/II trial","volume":"33","author":"Ahn","year":"2022","journal-title":"Ann Oncol"},{"key":"R66-20260213","doi-asserted-by":"crossref","first-page":"101470","DOI":"10.1016\/j.xcrm.2024.101470","article-title":"KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: a multicenter phase 2 trial","volume":"5","author":"Zhao","year":"2024","journal-title":"Cell Rep Med"},{"key":"R67-20260213","doi-asserted-by":"crossref","first-page":"100762","DOI":"10.1016\/j.iotech.2024.100762","article-title":"133P The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced nonsmall cell lung cancer: a single-arm, open-label, multicenter phase II clinical trial","volume":"24","author":"Zhang","year":"2024","journal-title":"Immuno Oncol Technol"},{"issue":"(Suppl 16)","key":"R68-20260213","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1200\/JCO.2025.43.16_suppl.8521","article-title":"First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic nonsmall cell lung cancer (a\/mNSCLC): results from TROPION-Lung04 (cohort 5)","volume":"43","author":"Waqar","year":"2025","journal-title":"J Clin Oncol"},{"key":"R69-20260213","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1634\/theoncologist.2013-0096","article-title":"Second-line therapy for advanced NSCLC","volume":"18","author":"Weiss","year":"2013","journal-title":"Oncologist"},{"key":"R70-20260213","first-page":"3831","article-title":"Docetaxel in the treatment of nonsmall cell lung cancer (NSCLC) -- an observational study focusing on symptom improvement","volume":"33","author":"Pircher","year":"2013","journal-title":"Anticancer Res"},{"key":"R71-20260213","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1183\/09031936.00132008","article-title":"First- and second-line therapy for advanced nonsmall cell lung cancer","volume":"33","author":"Sculier","year":"2009","journal-title":"Eur Respir J"},{"key":"R72-20260213","first-page":"4","article-title":"Historical evolution of second-line therapy in non-small cell lung cancer","volume":"4","author":"Lazzari","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"R73-20260213","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"R74-20260213","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41423-020-00577-5","article-title":"The cutting-edge progress of immune-checkpoint blockade in lung cancer","volume":"18","author":"Zhou","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"R75-20260213","doi-asserted-by":"crossref","first-page":"e472792","DOI":"10.1200\/EDBK-25-472792","article-title":"Bispecific antibodies in non\u2013small cell lung cancer: from targeted innovation to real-world integration","volume":"45","author":"Carlisle","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R76-20260213","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/curroncol32040206","article-title":"Unveiling the synergistic potential: bispecific antibodies in conjunction with chemotherapy for advanced non-small-cell lung cancer treatment","volume":"32","author":"Khan","year":"2025","journal-title":"Curr Oncol"},{"key":"R77-20260213","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"R78-20260213","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"R79-20260213","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized Phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"key":"R80-20260213","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive nonsmall-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir Med"},{"key":"R81-20260213","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced nonsmall cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"R82-20260213","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced nonsmall cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"R83-20260213","doi-asserted-by":"crossref","first-page":"100641","DOI":"10.1016\/j.jbc.2021.100641","article-title":"Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET","volume":"296","author":"Neijssen","year":"2021","journal-title":"J Biol Chem"},{"key":"R84-20260213","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"issue":"(Suppl 16)","key":"R86-20260213","doi-asserted-by":"crossref","first-page":"8639","DOI":"10.1200\/JCO.2025.43.16_suppl.8639","article-title":"Amivantamab plus chemotherapy vs chemotherapy in <i>EGFR<\/i>-mutant advanced NSCLC after disease progression on osimertinib: outcomes by osimertinib resistance mechanisms in MARIPOSA-2","volume":"43","author":"Califano","year":"2025","journal-title":"J Clin Oncol"},{"key":"R87-20260213","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the Phase III PALOMA-3 Study","volume":"42","author":"Leighl","year":"2024","journal-title":"J Clin Oncol"},{"issue":"(Suppl 16)","key":"R89-20260213","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1200\/JCO.2024.42.16_suppl.8604","article-title":"Efficacy and safety of MCLA-129, an EGFR\/c-MET bispecific antibody, in advanced nonsmall cell lung cancer (NSCLC)","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"R90-20260213","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial","volume":"332","author":"Fang","year":"2024","journal-title":"JAMA"},{"key":"R91-20260213","doi-asserted-by":"crossref","first-page":"S767","DOI":"10.1016\/j.annonc.2023.09.2363","article-title":"1330P Updated results of the efficacy and safety of KN046 (a bispecific anti-PD-L1\/CTLA-4) in patients with metastatic nonsmall cell lung cancer (NSCLC) who failed prior EGFR-TKI(s)","volume":"34","author":"Zhou","year":"2023","journal-title":"Ann Oncol"},{"issue":"(Suppl 16)","key":"R92-20260213","doi-asserted-by":"crossref","first-page":"e14506","DOI":"10.1200\/JCO.2024.42.16_suppl.e14506","article-title":"IMM2510, an anti-PD-L1\/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: a phase I dose-escalation study","volume":"42","author":"Liu","year":"2024","journal-title":"J Clin Oncol"},{"key":"R93-20260213","doi-asserted-by":"crossref","first-page":"S758","DOI":"10.1016\/j.annonc.2023.09.2350","article-title":"1316MO BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with nonsmall cell lung cancer: updated results from first-in-human phase I study","volume":"34","author":"Zhang","year":"2023","journal-title":"Ann Oncol"},{"key":"R94-20260213","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12916-017-0954-x","article-title":"Comparative efficacy and safety of second-line treatments for advanced nonsmall cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis","volume":"15","author":"Cr\u00e9quit","year":"2017","journal-title":"BMC Med"},{"key":"R95-20260213","doi-asserted-by":"crossref","first-page":"102106","DOI":"10.1016\/j.eclinm.2023.102106","article-title":"AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced nonsmall cell lung cancer (NSCLC): an open-label, multicenter, phase II trial","volume":"62","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"(Suppl 16)","key":"R96-20260213","first-page":"2533","article-title":"Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic nonsmall cell lung cancer (mNSCLC): initial results of a randomized, open-label, phase 2 trial JT J Clin Oncol","volume":"42","author":"Aerts","year":"2024"},{"issue":"(Suppl 16)","key":"R97-20260213","doi-asserted-by":"crossref","first-page":"9025","DOI":"10.1200\/JCO.2023.41.16_suppl.9025","article-title":"SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR\/ALK wild-type nonsmall cell lung cancer: a phase II, multicenter, open-label study","volume":"41","author":"Zhao","year":"2023","journal-title":"J Clin Oncol"},{"key":"R98-20260213","article-title":"Izalontamab (SI-B001), a novel EGFRxHER3 bispecific antibody in patients with Locally Advanced or Metastatic Epithelial Tumor: results from first-in-human phase I\/Ib study","author":"Xue","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"(Suppl 16)","key":"R99-20260213","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1200\/JCO.2025.43.16_suppl.2609","article-title":"Bispecific innate cell engager (ICE) AFM24 in combination with atezolizumab in patients with advanced\/metastatic <i>EGFR<\/i>-expressing nonsmall cell lung cancer (NSCLC) without driver mutations: initial results from a phase 2a study","volume":"43","author":"Kim","year":"2025","journal-title":"J Clin Oncol"},{"key":"R100-20260213","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS Phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J Clin Oncol"},{"key":"R101-20260213","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jtho.2025.05.012","article-title":"Amivantamab in participants with advanced NSCLC and MET exon 14 skipping mutations: final results from the CHRYSALIS Study","volume":"20","author":"Krebs","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R102-20260213","doi-asserted-by":"crossref","first-page":"S828","DOI":"10.1016\/j.annonc.2024.08.1359","article-title":"1302P MET\u00d7MET bispecific antibody davutamig (REGN5093) for MET-altered advanced nonsmall cell lung cancer (aNSCLC): update from a first-in-human (FIH) study","volume":"35","author":"Cho","year":"2024","journal-title":"Ann Oncol"},{"key":"R103-20260213","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of zenocutuzumab in NRG1 fusion-positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl J Med"},{"key":"R105-20260213","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jtho.2024.12.029","article-title":"Amivantamab plus lazertinib in patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy: results from CHRYSALIS-2 Cohort A","volume":"20","author":"Besse","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"(Suppl 16)","key":"R106-20260213","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1200\/JCO.2023.41.16_suppl.2533","article-title":"Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: interim results for the nonsmall cell lung cancer (NSCLC) cohort","volume":"41","author":"El-Khoueiry","year":"2023","journal-title":"J Clin Oncol"},{"key":"R107-20260213","doi-asserted-by":"crossref","first-page":"S829","DOI":"10.1016\/j.annonc.2023.09.2490","article-title":"1459P Preliminary efficacy and safety of KN046 (a bispecific anti-PD-L1\/CTLA-4) in patients with metastatic nonsmall cell lung cancer who previously treated with immune checkpoint inhibitor(s)","volume":"34","author":"Zhou","year":"2023","journal-title":"Ann Oncol"},{"key":"R108-20260213","doi-asserted-by":"crossref","first-page":"S1646","DOI":"10.1016\/j.annonc.2024.10.680","article-title":"647P A phase Ib\/II study of second-line cadonilimab, anlotinib and docetaxel in patients with checkpoint inhibitor (CPI)-experienced advanced nonsmall cell lung cancer","volume":"35","author":"Han","year":"2024","journal-title":"Ann Oncol"},{"key":"R109-20260213","doi-asserted-by":"crossref","first-page":"S822","DOI":"10.1016\/j.annonc.2023.09.2477","article-title":"1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced\/metastatic nonsmall-cell lung cancer (NSCLC): ARTEMIDE-01","volume":"34","author":"Brand\u00e3o","year":"2023","journal-title":"Ann Oncol"},{"key":"R110-20260213","doi-asserted-by":"crossref","first-page":"107355","DOI":"10.1016\/j.lungcan.2023.107355","article-title":"A multicenter, open-label phase Ib\/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced nonsmall-cell lung cancer (AK104-202 study)","volume":"184","author":"Zhao","year":"2023","journal-title":"Lung Cancer"},{"key":"R111-20260213","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1038\/s41591-023-02593-0","article-title":"The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial","volume":"29","author":"Luke","year":"2023","journal-title":"Nat Med"},{"issue":"(Suppl 16)","key":"R112-20260213","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1200\/JCO.2025.43.16_suppl.8509","article-title":"First-in-class PD-1\/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated nonsmall cell lung cancer (NSCLC)","volume":"43","author":"Zhou","year":"2025","journal-title":"J Clin Oncol"},{"key":"R113-20260213","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jtho.2020.03.003","article-title":"Bintrafusp Alfa, a bifunctional fusion protein targeting TGF-( and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a Phase 1 trial","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"(Suppl 12)","key":"R114-20260213","doi-asserted-by":"crossref","first-page":"CT513","DOI":"10.1158\/1538-7445.AM2022-CT513","article-title":"Abstract CT513: Phase I study of IBI322\u200a(anti-CD47\/PD-L1 bispecific antibody) monotherapy therapy in patients with advanced solid tumors in China","volume":"82","author":"Wang","year":"2022","journal-title":"Cancer Res"},{"key":"R116-20260213","doi-asserted-by":"crossref","first-page":"277","DOI":"10.21037\/tlcr-22-75","article-title":"Neoadjuvant immunotherapy or chemoimmunotherapy in nonsmall cell lung cancer: a systematic review and meta-analysis","volume":"11","author":"Jiang","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"R117-20260213","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ccell.2024.05.024","article-title":"Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III nonsmall-cell lung cancer: a proof-of-concept, phase 2 trial","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"issue":"(Suppl 16)","key":"R118-20260213","doi-asserted-by":"crossref","first-page":"8082","DOI":"10.1200\/JCO.2024.42.16_suppl.8082","article-title":"Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial","volume":"42","author":"Wu","year":"2024","journal-title":"J Clin Oncol"},{"key":"R119-20260213","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrclinonc.2017.71","article-title":"Unravelling the biology of SCLC: implications for therapy","volume":"14","author":"Sabari","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"R120-20260213","doi-asserted-by":"crossref","first-page":"17588359251326705","DOI":"10.1177\/17588359251326705","article-title":"Current and future perspectives in extensive-stage small-cell lung cancer","volume":"17","author":"Lim","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"R121-20260213","doi-asserted-by":"crossref","first-page":"e009667","DOI":"10.1136\/jitc-2024-009667","article-title":"New developments in immunotherapy for SCLC","volume":"13","author":"Dolkar","year":"2025","journal-title":"J Immunother Cancer"},{"key":"R122-20260213","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: an emerging target in small cell lung cancer","volume":"12","author":"Owen","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R123-20260213","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"R124-20260213","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"R126-20260213","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jtho.2024.10.013","article-title":"Brief report: ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage SCLC: results of a Phase 1b clinical trial","volume":"20","author":"Chen","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"(Suppl 16)","key":"R127-20260213","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2025.43.16_suppl.3002","article-title":"Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC)","volume":"43","author":"Huang","year":"2025","journal-title":"J Clin Oncol"},{"key":"R128-20260213","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1158\/0008-5472.CAN-23-2701","article-title":"ATG-101 is a tetravalent PD-L1\u200a\u00d7\u200a4-1BB bispecific antibody that stimulates antitumor immunity through PD-L1 blockade and PD-L1-directed 4-1BB activation","volume":"84","author":"Yuwen","year":"2024","journal-title":"Cancer Res"},{"issue":"Suppl 2","key":"R129-20260213","first-page":"A1210","article-title":"1210 A human bispecific antibody targeting LAG-3 and PD-1 (INCA32459) potently activates exhausted T cells","volume":"10","author":"Shaun","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R130-20260213","doi-asserted-by":"crossref","first-page":"S810","DOI":"10.1016\/j.annonc.2024.08.1322","article-title":"1265P A promising MET-EGFR bispecific nanobody-drug conjugate therapy for multiple solid tumours","volume":"35","author":"Cai","year":"2024","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"R131-20260213","first-page":"A1150","article-title":"1150 DM005, an EGFR\u200a\u00d7\u200aMET bispecific antibody-drug conjugate, showed robust antitumor activity in PDX models","volume":"11","author":"Yanfei","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"(Suppl 12)","key":"R132-20260213","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/1538-7445.AM2022-2908","article-title":"Abstract 2908: PT217, an anti-DLL3\/anti-CD47 bispecific antibody, exhibits antitumor activity through novel mechanisms of action","volume":"82","author":"Jia","year":"2022","journal-title":"Cancer Res"},{"issue":"(8_Suppl_1)","key":"R133-20260213","doi-asserted-by":"crossref","first-page":"7299","DOI":"10.1158\/1538-7445.AM2025-7299","article-title":"Abstract 7299: CS2009: A first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFA with potential to be a next-generation backbone therapy with combined checkpoint inhibition and antiangiogenesis","volume":"85","author":"Wang","year":"2025","journal-title":"Cancer Res"},{"key":"R134-20260213","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.annonc.2022.02.031","article-title":"22P EMB-01: an EGFR-cMET bispecific antibody, in advanced\/metastatic solid tumors phase I results","volume":"33","author":"Qing","year":"2022","journal-title":"Ann Oncol"},{"issue":"(Suppl 1)","key":"R135-20260213","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1182\/blood-2022-169658","article-title":"First-in-human phase I trial of a ROR1 targeting bispecific T cell engager (NVG-111) in combination with ibrutinib or as monotherapy in subjects with relapsed refractory chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL)","volume":"140","author":"Townsend","year":"2022","journal-title":"Blood"},{"issue":"(Suppl 16)","key":"R136-20260213","article-title":"SI-B003\u200a(PD-1\/CTLA-4) in patients with advanced solid tumors: a phase I study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"(Suppl 16)","key":"R137-20260213","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2024.42.16_suppl.3031","article-title":"Evaluation of the safety, pharmacokinetics, and efficacy of JSKN003 in patients with advanced solid tumors: a phase I\/II clinical study","volume":"42","author":"Liu","year":"2024","journal-title":"J Clin Oncol"},{"key":"R138-20260213","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/cancers13020287","article-title":"Overcoming challenges for CD3-bispecific antibody therapy in solid tumors","volume":"13","author":"Middelburg","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R139-20260213","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-021-01067-5","article-title":"CAR-T cells and BiTEs in solid tumors: challenges and perspectives","volume":"14","author":"Edeline","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R140-20260213","doi-asserted-by":"crossref","first-page":"245","DOI":"10.6004\/jadpro.2024.15.4.2","article-title":"Infusion-related reaction management with amivantamab for EGFR Exon 20 insertion mutation NSCLC: a practical guide for advanced practitioners","volume":"15","author":"Dougherty","year":"2024","journal-title":"J Adv Pract Oncol"},{"key":"R141-20260213","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.lungcan.2023.02.008","article-title":"Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study","volume":"178","author":"Park","year":"2023","journal-title":"Lung Cancer"},{"key":"R142-20260213","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cllc.2022.01.003","article-title":"Safety of MET tyrosine kinase inhibitors in patients with MET exon 14 skipping nonsmall cell lung cancer: a clinical review","volume":"23","author":"Cortot","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"R143-20260213","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11523-022-00912-y","article-title":"Management of peripheral edema in patients with MET exon 14-mutated nonsmall cell lung cancer treated with small molecule MET inhibitors","volume":"17","author":"Nishio","year":"2022","journal-title":"Target Oncol"},{"key":"R144-20260213","doi-asserted-by":"crossref","DOI":"10.1007\/s11523-025-01163-3","article-title":"Dermatologic adverse event mitigation and management strategies with amivantamab + lazertinib therapy for advanced non-small cell lung cancer: a Vodcast","author":"Nguyen","year":"2025","journal-title":"Target Oncol"},{"key":"R145-20260213","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cpt.3308","article-title":"Clinical pharmacology strategies for bispecific antibody development: learnings from FDA-approved bispecific antibodies in oncology","volume":"116","author":"Lim","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"R146-20260213","doi-asserted-by":"crossref","first-page":"e004225","DOI":"10.1136\/jitc-2021-004225","article-title":"Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology","volume":"10","author":"Zhou","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R147-20260213","doi-asserted-by":"crossref","first-page":"e472794","DOI":"10.1200\/EDBK-25-472794","article-title":"Taking a bite out of small cell lung cancer by leveraging precision-directed delta-like ligand-3 therapies","volume":"45","author":"Aijaz","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R148-20260213","doi-asserted-by":"crossref","first-page":"1368804","DOI":"10.3389\/fonc.2024.1368804","article-title":"Cost-effectiveness analysis of amivantamab plus chemotherapy versus chemotherapy alone in NSCLC with EGFR Exon 20 insertions","volume":"14","author":"Yue","year":"2024","journal-title":"Front Oncol"},{"key":"R149-20260213","doi-asserted-by":"crossref","first-page":"e244461","DOI":"10.1001\/jamahealthforum.2024.4461","article-title":"Launch and Postlaunch Price Developments of New Drugs in the US, Germany, and Switzerland","volume":"5","author":"Laube","year":"2024","journal-title":"JAMA Health Forum"},{"key":"R150-20260213","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.jtho.2024.09.187","article-title":"MA12.07 amivantamab plus lazertinib vs osimertinib in first-line, EGFR-mutant advanced NSCLC: patient-relevant outcomes from MARIPOSA","volume":"19","author":"Nguyen","year":"2024","journal-title":"J Thorac Oncol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000001206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:00:56Z","timestamp":1770984056000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000001206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":138,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000001206","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]}}}